Alaunos Therapeutics (TCRT) Stock: Buy, Sell, or Hold?
TCRT - Alaunos Therapeutics, Inc. Common Stock
$3.13
0.50 (19.01%)
▲
5d:
+198.1%
30d:
+160.83%
90d:
+49.76%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 13, 2026
24d
Get Alerted When TCRT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: TCRT is 55.0% above its trading range ($2.02). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: TCRT is 55.0% above its trading range ($2.02). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: TCRT is currently trading at $3.13, which is considered extended relative to its 30-day fair value range of $0.73 to $2.02.
Technical Outlook: Technically, TCRT is in a downtrend. Immediate support is located at $0.72, while resistance sits at $4.40. The stock is showing strong short-term momentum, up 19.0% recently.
Market Sentiment: TCRT scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $1.75. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TCRT is in a downtrend. Immediate support is located at $0.72, while resistance sits at $4.40. The stock is showing strong short-term momentum, up 19.0% recently.
Market Sentiment: TCRT scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $1.75. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.73 -
$2.02
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
10.5%
All Signals
- BEARISH: Price significantly overextended (+55.0% above its trading range)
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+19.0%)
- BEARISH: Trading 44.1% above Wall St target ($1.75)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.73 -
$2.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$4.40
Current Trend
Downtrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.48
Wall Street Target
$1.75
(-44.1%)
Revenue Growth (YoY)
-25.0%
Share & Embed Analysis
Last updated: October 19, 2026 5:09 PM ET
Data refreshes hourly during market hours. Next update: 6:09 PM
Data refreshes hourly during market hours. Next update: 6:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 65 BUY |
|
BCAX
Bicara Therapeutics Inc.… |
STRONG BUY
14 analysts |
$36 | 64 BUY |
